Endocrinology, Vol 102, 1748-1758, Copyright © 1978 by Endocrine Society

ARTICLES

Studies on the mechanism of 3 alpha-androstanediol-induced growth of the dog prostate

GH Jacobi, RJ Moore and JD Wilson

The conditions under which dihydrotestosterone and 5 alpha-androstane-3 alpha, 17 beta-diol (3 alpha-androstanediol) induce prostatic growth in the castrate dog have been investigated in animals in which the initial size of the prostate was either normal or large. When androgen replacement was commenced immediately after castration of dogs with preexisting prostatic hypertrophy, dihydrotestosterone was as effective as 3 alpha-androstanediol in maintaining prostate weight. Under all other conditions examined (replacement commenced immediately after castration in dogs with small prostates or 2 weeks after castration in dogs with large prostates), 3 alpha-androstanediol but not dihydrotestosterone induced significant prostatic growth. The maximal effect of 3 alpha-androstanediol in inducing prostatic growth was observed in 12 weeks. The administration of 17 beta-estradiol enhanced the growth-promoting action of 3 alpha-androstanediol, but did not affect the action of dihydrotestosterone or influence 3 alpha- hydroxysteroid dehydrogenase activity in prostate. Thus, the synergistic effect of 17 beta-estradiol and 3 alpha-androstanediol seems to be independent of any effect on the interconversion of the two androgens. The activity of the 3 alpha-hydroxysteroid dehydrogenase in dog prostate was high under all conditions of accelerated prostatic growth and appeared to be under androgenic control.

This article has been cited by other articles:

				D. R. Bauman, S. Steckelbroeck, D. M. Peehl, and T. M. Penning Transcript Profiling of the Androgen Signal in Normal Prostate, Benign Prostatic Hyperplasia, and Prostate Cancer Endocrinology, December 1, 2006; 147(12): 5806 - 5816. [Abstract] [Full Text] [PDF]

				K-M Fung, E N S Samara, C Wong, A Metwalli, R Krlin, B Bane, C Z Liu, J T Yang, J V Pitha, D J Culkin, et al. Increased expression of type 2 3{alpha}-hydroxysteroid dehydrogenase/type 5 17{beta}-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr. Relat. Cancer, March 1, 2006; 13(1): 169 - 180. [Abstract] [Full Text] [PDF]

				D. R. Bauman, S. Steckelbroeck, M. V. Williams, D. M. Peehl, and T. M. Penning Identification of the Major Oxidative 3{alpha}-Hydroxysteroid Dehydrogenase in Human Prostate That Converts 5{alpha}-Androstane-3{alpha},17{beta}-diol to 5{alpha}-Dihydrotestosterone: A Potential Therapeutic Target for Androgen-Dependent Disease Mol. Endocrinol., February 1, 2006; 20(2): 444 - 458. [Abstract] [Full Text] [PDF]

				V. D. H. Ding, D. E. Moller, W. P. Feeney, V. Didolkar, A. M. Nakhla, L. Rhodes, W. Rosner, and R. G. Smith Sex Hormone-Binding Globulin Mediates Prostate Androgen Receptor Action via a Novel Signaling Pathway Endocrinology, January 1, 1998; 139(1): 213 - 218. [Abstract] [Full Text] [PDF]

				H.-K. Lin, J. M. Jez, B. P. Schlegel, D. M. Peehl, J. A. Pachter, and T. M. Penning Expression and Characterization of Recombinant Type 2 3{alpha}-Hydroxysteroid Dehydrogenase (HSD) from Human Prostate: Demonstration of Bifunctional 3{alpha}/17{beta}-HSD Activity and Cellular Distribution Mol. Endocrinol., December 1, 1997; 11(13): 1971 - 1984. [Abstract] [Full Text] [PDF]

				T. M. Penning Molecular Endocrinology of Hydroxysteroid Dehydrogenases Endocr. Rev., June 1, 1997; 18(3): 281 - 305. [Abstract] [Full Text]

				G. Shaw, M. B. Renfree, M. W. Leihy, C. H. L. Shackleton, E. Roitman, and J. D. Wilson Prostate formation in a marsupial is mediated by the testicular androgen 5alpha -androstane-3alpha ,17beta -diol PNAS, October 24, 2000; 97(22): 12256 - 12259. [Abstract] [Full Text] [PDF]